Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practicing in specific cardiology domains.
Barcelona, Spain – 28 Aug 2017: The benefit of lowering low-density lipoprotein (LDL) cholesterol depends on how it is lowered, according to late-breaking results from a naturally randomised genetic trial presented today in a Hot Line - LBCT Session at ESC Congress (1) and published in JAMA.
“Our study suggests that the causal effect of LDL on the risk of cardiovascular disease (CVD) is determined by the circulating concentration of LDL particles, measured by apolipoprotein-B (apoB), rather than by the total cholesterol carried by those particles, as measured by LDL cholesterol,” said the study’s lead investigator Prof Brian A Ference, the Benjamin Meaker Visiting Professor, University of Bristol, UK and Director of the Cardiovascular Genomic Research Center, Wayne State University School of Medicine, Detroit, US.
“Therefore, the clinical benefit of LDL cholesterol lowering therapies may depend on the corresponding reduction in apoB particles, which in turn depend on how LDL cholesterol is lowered,” he continued.
In the ACCELERATE trial, treatment with the cholesteryl ester transfer protein (CETP) inhibitor evacetrapib reduced LDL cholesterol by 39% (0.75 mmol/L) but did not reduce the risk of major cardiovascular events. (2) The results led some people to question the causal effect of LDL cholesterol on the risk of developing CVD and suggested that the clinical benefit of lowering LDL cholesterol may depend on how it is lowered.
The current study sought to determine if lowering LDL cholesterol by inhibiting CETP had the same effect on the risk of CVD as other LDL cholesterol lowering therapies, and thereby determine if the clinical benefit of lowering LDL cholesterol depends on how LDL cholesterol is lowered.
The study included a total of 358 205 participants from 77 studies. The researchers used inherited genetic variants that mimic the effect of CETP inhibitors and statins, respectively, to naturally randomise participants into four groups: CETP inhibition (mimicking the effect of a CETP inhibitor), HMG-CoA reduction inhibition (mimicking the effect of a statin), both (mimicking the effect of combined CETP inhibitor and statin therapy) or neither (placebo group) using a 2x2 factorial Mendelian randomisation study design.
The primary outcome was major cardiovascular events (defined as the first occurrence of coronary heart disease death, non-fatal myocardial infarction, coronary revascularisation or non-fatal stroke). Study participants experienced a total of 76 061 cardiovascular events.
The investigators found that genetic variants that mimic the effect of CETP inhibitors were associated with higher high-density lipoprotein (HDL) cholesterol, lower LDL cholesterol, lower apoB and a corresponding lower risk of CVD that was proportional to the reduction in LDL cholesterol. In fact, genetic variants that mimic the effect of CETP inhibitors had a very similar effect on reducing the risk of cardiovascular events as genetic variants that mimic the effect of statins, ezetimibe and PCSK9 inhibitors when measured per unit reduction in LDL cholesterol.
However, the CETP inhibitor trials have evaluated their effect on a background of statins so the investigators also examined the combined effect of genetic variants that mimic the effect of CETP inhibitors and statins. Combined exposure was associated with the same decrease in LDL cholesterol but the change in apoB was significantly attenuated. The risk of cardiovascular events was proportional to the change in apoB but less than expected per unit change in LDL cholesterol. This suggests that the causal effect of lowering LDL cholesterol is determined by reduction in apoB, not LDL cholesterol.
The findings were validated in a genome-wide association study which found that other variants with discordant effects on LDL cholesterol and apoB were also associated with a lower risk of CVD that was proportional to the change in apoB but less than expected per unit change in LDL cholesterol.
Prof Ference said: “These results may help to explain the failure of some CETP inhibitors to reduce the risk of cardiovascular events despite robustly lowering LDL cholesterol. Adding a CETP inhibitor to a statin reduces LDL cholesterol out of proportion to apoB. Because the clinical benefit is determined by the reduction in apoB, rather than LDL cholesterol, combination therapy with a CETP inhibitor and a statin reduces the risk of cardiovascular events proportional to the attenuated reduction in apoB. This may be significantly less than expected for the observed change in LDL cholesterol depending on the degree of discordance between the reductions in apoB and LDL cholesterol.” (3)
Sources of funding: None.
Disclosures: Dr Ference reports receiving research grants from Merck, Amgen, Novartis and Esperion Therapeutics; and consulting fees from Merck, Amgen, Esperion, Ionis, Sanofi, Regeneron, and KrKa Pharmaceuticals.
References and notes:(1) The study “A Naturally Randomized Trial Comparing the Effect of Genetic Variants that Mimic CETP Inhibitors and Statins on the Risk of Cardiovascular Disease” will be presented during:• The press conference Hot Line: Late Breaking Clinical Trials 3 on Monday 28 August from 08:00 to 09:00.• The session Hot Line: Late Breaking Clinical Trials 3 on Monday 28 August from 14:00 to 15:30 in Barcelona – Main Auditorium.(2) Lincoff AM, et al. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med. 2017;376:1933–1942.(3) Therapies that reduce LDL cholesterol by reducing LDL particle concentration, such as statins, ezetimibe and PCSK9 inhibitors should reduce CVD risk proportional to the absolute change in either LDL cholesterol or apoB, because these changes are concordant. By contrast, therapies that reduce LDL cholesterol without proportionally reducing LDL particles, for example by altering the lipid content of LDL particles as occurs when a CETP inhibitor is added to a statin, should reduce the CVD risk proportional to the absolute change in apoB – this risk reduction may be less than expected per unit change in LDL cholesterol because the changes in LDL cholesterol and apoB will be discordant.
ESC Press OfficeFor more information, please contact the ESC Press Office: email@example.com.For press enquiries, independent comment on-site, please contact, the Media & Press Coordinator Jacques Olivier COSTA: +34 666 509 856The press conference timetable is available here.
To access all the scientific resources from the sessions during the congress, visit ESC Congress 365. About the European Society of CardiologyThe European Society of Cardiology brings together health care professionals from more than 140 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.About ESC Congress 2017ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2017 takes place 26 to 30 August at the Fira Gran Via in Barcelona, Spain. The scientific programme is here. More information is available from the ESC Press Office at firstname.lastname@example.org.This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2017. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved